Business Description
Founded in 2011 and headquartered in Cambridge, Massachusetts, Cypherpunk Technologies Inc. builds and invests in privacy-focused digital technologies, with Zcash serving as the foundation of its digital asset holdings. The company also researches and develops antibody-based treatments targeting cancer and related conditions, including DKN-01, which has completed a Phase 2 trial for colorectal cancer, and FL-501, an early-stage therapy aimed at cancer-related weight loss, severe pregnancy nausea, and conditions linked to aging. Previously operating as Leap Therapeutics, the company adopted its current name in November 2025.
